The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a twice-yearly therapy that allows administration during patients routine visits to their healthcare professionals and potentially contributes to improved patient adherence and sustained lower LDL-C levels. The Company is a subsidiary of Novartis AG.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.14%	-0.05%

06/01/20	The Medicines Company Announces Board Changes	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	CI

Capitalization	6.79B 5.86B 5.29B 5.07B 9.21B 626B 9.63B 62.45B 25.04B 299B 25.49B 24.94B 1,074B	P/E ratio 2017	-2.79x	P/E ratio 2018	-11.4x
Enterprise value	7.34B 6.33B 5.72B 5.48B 9.96B 676B 10.42B 67.53B 27.08B 324B 27.56B 26.97B 1,161B	EV / Sales 2017	55.1x	EV / Sales 2018	319x
Free-Float	92.97%	Yield 2017 *	-	Yield 2018	-

06/01/20	The Medicines Company Announces Board Changes	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from S&P TMI Index	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 1000	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Global BMI Index	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Composite 1500	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Biotechnology Select Industry Index	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from NASDAQ Biotechnology Index	CI
06/01/20	The Medicines Company(NasdaqGS:MDCO) dropped from NASDAQ Composite Index	CI
02/01/20	Novartis AG completed the acquisition of The Medicines Company.	CI
25/11/19	World share markets rally on revived trade hopes; dollar gains	RE
25/11/19	World share markets rally on revived trade hopes; dollar gains	RE

19/04/24	Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases	AQ
07/01/20	The Medicines Company : Announces Effective Date of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022	AQ
06/01/20	The Medicines Company : Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024	BU
06/01/20	MEDICINES CO /DE : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
06/01/20	MEDICINES CO /DE : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

The Medicines Company Share Price

Equities

MDCO

US5846881051

Pharmaceuticals

Valuation: The Medicines Company

Latest news: The Medicines Company

Press Releases: The Medicines Company

News in other languages: The Medicines Company

Managers and Directors: The Medicines Company

Generic Pharmaceuticals

Financials

Company Profile

06/01/20	Medicines : Novartis bringt Übernahme von US-Biotech-Firma in trockene Tücher
30/12/19	Les fusions-acquisitions soutenues par la vigueur du marché américain en 2019
05/12/19	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
26/11/19	Des marchés dopés à l'optimisme
25/11/19	Point marchés-Les actions profitent des espoirs sur le commerce et des M&A

Manager	Title	Age	Since
Krishna Gorti IRC	Investor Relations Contact	-	-
Stephen M. Rodin LAW	General Counsel	49	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.30%	+3.56%	+12.49%	+89.71%	47.07B
OTSUKA HOLDINGS CO., LTD.	+3.24%	+0.54%	+37.87%	+152.04%	32.94B
SAM CHUN DANG PHARM. CO., LTD	+0.39%	-7.03%	+294.34%	+1,245.61%	12.08B
CIPLA LIMITED	+0.64%	+1.55%	-8.84%	+51.33%	11.62B
ZYDUS LIFESCIENCES LIMITED	+1.57%	+2.92%	+3.29%	+94.38%	9.93B
KRKA, D. D.	-0.43%	-1.29%	+36.72%	+120.19%	8.09B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-3.37%	+0.61%	+65.71%	+43.07%	7.93B
ONO PHARMACEUTICAL CO., LTD.	-2.72%	-3.14%	+40.40%	-15.47%	7.36B
GLENMARK PHARMACEUTICALS LIMITED	+5.11%	+9.12%	+58.63%	+419.26%	6.49B
Average	+0.47%	+0.33%	+60.07%	+244.46%	15.03B
Weighted average by Cap.	+0.88%	+0.09%	+47.50%	+207.18%

	2017	2018
Net sales	44.79M 38.63M 34.89M 33.44M 60.77M 4.13B 63.54M 412M 165M 1.97B 168M 165M 7.08B	6.14M 5.29M 4.78M 4.58M 8.33M 565M 8.71M 56.45M 22.64M 270M 23.04M 22.55M 971M
Net income	-708M -611M -552M -529M -961M -65.26B -1B -6.51B -2.61B -31.22B -2.66B -2.6B -112B	-123M -106M -95.93M -91.94M -167M -11.35B -175M -1.13B -454M -5.43B -462M -452M -19.48B
Net Debt	498M 429M 388M 372M 675M 45.86B 706M 4.58B 1.84B 21.94B 1.87B 1.83B 78.73B	552M 476M 430M 412M 749M 50.84B 783M 5.07B 2.04B 24.32B 2.07B 2.03B 87.27B